

1 ***cfTrack*: Exome-wide mutation analysis of cell-free DNA to simultaneously monitor**
2 **the full spectrum of cancer treatment outcomes: MRD, recurrence, and evolution**
3
4 **Shuo Li^{1,2,3}, Weihua Zeng¹, Xiaohui Ni³, Yonggang Zhou¹, Mary L. Stackpole^{1,2,3}, Zorawar S.**
5 **Noor⁴, Zuyang Yuan¹, Adam Neal^{5,7}, Sanaz Memarzadeh^{5,6,7,8,11}, Edward B. Garon⁴, Steven**
6 **M. Dubinett^{1,4,9,10,11,12}, Wenyuan Li¹, Xianghong Jasmine Zhou^{1,*}**

7
8 ¹Department of Pathology and Laboratory Medicine, David Geffen School of Medicine, University of
9 California at Los Angeles, Los Angeles, CA 90095, USA; ²Bioinformatics Interdepartmental Graduate
10 Program, University of California at Los Angeles, Los Angeles, CA 90095, USA; ³EarlyDiagnostics
11 Inc. ,Los Angeles, CA 90095, USA; ⁴Department of Medicine, David Geffen School of Medicine at
12 UCLA, Los Angeles, CA 90095, USA; ⁵Department of Obstetrics and Gynecology, David Geffen
13 School of Medicine at UCLA, Los Angeles, CA 90095, USA; ⁶UCLA Jonsson Comprehensive Cancer
14 Center, University of California Los Angeles, Los Angeles, CA, 90095, USA; ⁷UCLA Eli and Edythe
15 Broad Center of Regenerative Medicine and Stem Cell Research, University of California Los Angeles,
16 Los Angeles, CA, 90095, USA; ⁸Molecular Biology Institute, University of California Los Angeles, Los
17 Angeles, CA, 90095, USA; ⁹Department of Pulmonary and Critical Care Medicine, David Geffen
18 School of Medicine at UCLA, Los Angeles, 90095, California, USA; ¹⁰Department of Molecular and
19 Medical Pharmacology, David Geffen School of Medicine at UCLA, Los Angeles, 90095, California,
20 USA; ¹¹VA Greater Los Angeles Health Care System, Los Angeles, California, 90073, USA;
21 ¹²Department of Microbiology, Immunology and Molecular Genetics, University of California at Los
22 Angeles, Los Angeles, CA 90095, USA.

23
24 **Correspondence Author:** Xianghong Jasmine Zhou. Mail address: 630 Charles E Young Dr S, Suite
25 33-251, Los Angeles, CA 90095; Phone: 310-267-0363; Email: XJZhou@mednet.ucla.edu.

26

27 **Conflict of interest.** X.J.Z. and W.L. are co-founders of EarlyDiagnostics Inc. X.N., M.L.S. is
28 employees at EarlyDiagnostics Inc. The other authors declare no competing interests.

29

30 **Translational Relevance**

31 Continuous cancer monitoring is clinically necessary for cancer patients to detect minimal residual
32 disease (MRD), recurrence, and progression, allowing for early intervention and therapy
33 adjustment. Cell-free DNA (cfDNA) in blood has become an appealing option due to its non-
34 invasiveness. Until now, cfDNA-based cancer monitoring methods have been focused on deep
35 sequencing at a few known mutations, which are however insufficient when tumors evolve or new
36 tumors emerge. We present the method, cfTrack, which for the first time uses whole-exome
37 sequencing (WES) of cfDNA to track the full range of cancer treatment outcomes, including MRD,
38 recurrence, evolution, and second primary cancer. We demonstrate that, even with very low tumor
39 fractions, cfTrack achieves sensitive and specific monitoring of tumor MRD/recurrence/evolution
40 based on both simulation data and a cohort of cancer patients. These findings demonstrate the
41 clinical utility of cfTrack.

42

43

44 **Abstract**

45 Purpose: Cell-free DNA (cfDNA) offers a non-invasive approach to monitor cancer. Here we
46 develop a method using whole-exome sequencing (WES) of cfDNA for simultaneously monitoring
47 the full spectrum of cancer treatment outcomes, including MRD, recurrence, evolution, and
48 second primary cancer.

49 Experimental Design: Three simulation datasets were generated from 26 cancer patients to
50 benchmark the detection performance of MRD/recurrence and second primary cancers. For
51 further validation, cfDNA samples (n=76) from cancer patients (n=35) with six different cancer
52 types were used for validating the performance of cancer monitoring during various treatments.

53 Results: We present a cfDNA-based cancer monitoring method, named *cfTrack*. Taking
54 advantage of the broad genome coverage of WES data, *cfTrack* can sensitively detect MRD and
55 cancer recurrence by integrating signals across the known clonal tumor mutations of a patient. In
56 addition, *cfTrack* detects tumor evolution and second primary cancers by *de novo* identifying
57 emerging tumor mutations. A series of machine learning and statistical denoising techniques are
58 applied to enhance the detection power. On the simulation data, *cfTrack* achieved an average
59 AUC of 99% on the validation dataset and 100% on the independent dataset in detecting
60 recurrence in samples with tumor fraction $\geq 0.05\%$. In addition, *cfTrack* yielded an average AUC
61 of 88% in detecting second primary cancers in samples with tumor fraction $\geq 0.2\%$. On real data,
62 *cfTrack* accurately monitors tumor evolution during treatment, which cannot be accomplished by
63 previous methods.

64 Conclusion: Our results demonstrated that *cfTrack* can sensitively and specifically monitor the full
65 spectrum of cancer treatment outcomes using exome-wide mutation analysis of cfDNA.

66

67

68

69

70

71 **Introduction**

72

73 Despite the rapid development of cancer treatments, a large fraction of patients experiences
74 recurrence, resistance, or progression of cancer during or after treatment [1]. Even after the
75 surgical removal of tumors, a patient can still have minimal residual disease (MRD), which is
76 associated with an increased likelihood of recurrence [2]. Thus, cancer patients need continuous
77 monitoring in order to detect MRD, recurrence, and progression, thereby facilitating the early
78 intervention and the therapy adjustment [2][3]. Although cancer monitoring is clinically important,
79 the sequential sampling of tumor tissue from the patient poses a significant challenge. In this
80 context, liquid biopsy is an attractive option, especially the usage of **cell-free DNA (cfDNA)** in
81 blood. Blood samples can be obtained noninvasively for continuous monitoring, and the tumor-
82 derived DNA fragments in cfDNA can provide comprehensive genetic profiling even of
83 heterogeneous tumors [4].

84

85 However, a major challenge associated with cfDNA-based cancer monitoring is the low tumor
86 content. In cancer patients receiving treatment or with MRD, the fraction of tumor DNA in a cfDNA
87 sample can be as low as 0.1% [5]. Previous studies on cancer monitoring in plasma have used
88 deep sequencing on a small mutation panel to discover the weak tumor signal [2][5][6][7][8].
89 However, these methods have several crucial limitations: (1) the high cost of deep sequencing
90 restricts the panels to a small number of known mutations (either common cancer mutations or
91 mutations selected from the pre-treatment tumor sample of a specific patient); (2) personalized
92 panels usually require a labor-intensive experimental design; (3) panel-based monitoring cannot
93 detect emerging tumors with a different mutation profile, e.g., a second primary cancer, yet
94 approximately 30% patients develop a second primary cancer [9], driven by *de novo* tumor

95 mutations; and (4) panels usually set detection thresholds by studying a cohort of non-cancer
96 individuals, which exposes the test to systemic bias from inter-individual variations and inter-
97 experimental differences. Recently, two studies [10][11] presented cancer monitoring methods
98 using whole-genome sequencing, but they do not yet address limitations 3 and 4 mentioned
99 above, and focus on mutations seen in pre-treatment tumor samples. In addition, the high cost of
100 whole-genome sequencing limits the clinical applications of those two methods.

101
102 In this study, we describe a new cancer monitoring approach, named *cfTrack*, based on the cfDNA
103 whole-exome sequencing (WES). *cfTrack* addresses all the aforementioned limitations of existing
104 methods. Specifically, not only can it monitor the pre-existing cancer (i.e., the original, primary
105 cancer) to detect recurrence or MRD, but it can also monitor tumor evolution by detecting cancer
106 progression or the emergence of a second primary cancer. To monitor the pre-existing cancer,
107 *cfTrack* (1) uses exome-wide somatic mutations collected in pre-treatment samples (solid tumor
108 or blood samples) to provide a robust statistical index, then (2) models sample-specific
109 background noise in the cfDNA sequencing data to provide an unbiased detection threshold for
110 each patient. To monitor tumor evolution, *cfTrack* performs detection of exome-wide *de novo*
111 tumor mutations in the post-treatment plasma samples, using our recently developed *cfSNV*
112 method [12]. With exome-wide sequencing and comprehensive analysis of mutations, *cfTrack*
113 can sensitively identify these previously undiagnosed patients with second primary cancers,
114 comprehensively describe their tumor status, and enable early intervention and personalization
115 of treatment. Using both simulation data and a cohort of cancer patients (n = 35, 18 prostate
116 cancer, 8 lung cancer, 4 ovarian cancer, 3 glioma, 1 bladder cancer, and 1 germ cell cancer), we
117 show that *cfTrack* achieves sensitive and specific monitoring of tumor MRD/recurrence and
118 evolution from cfDNA, even with very low tumor fractions. These results demonstrate that *cfTrack*
119 enables full-spectrum monitoring of cancer treatment outcomes.

120

121 **Material and Methods**

122 **Data collection**

123 We collected WES data from four public datasets. We collected data of 18 metastatic cancer
124 patients from Adalsteinsson et al. [17] under dbGaP accession code phs001417.v1.p1. Each
125 patient's data includes a WBC sample, a tumor biopsy sample, and two plasma samples. We also
126 collected WES data of 3 cancer patients (1 bladder cancer, 1 prostate cancer, and 1 germ cell
127 cancer) from Tsui et al. [27] under dbGaP accession code phs002290 and WES data of 3 glioma
128 patients under SRA accession code SRP268702. Each patient has a WBC sample, a solid tumor
129 sample, and a plasma sample. We collected WES data of 17 prostate cancer patients from
130 Ramesh et al. [26] under SRA accession code SRP260849. All patients have one WBC sample;
131 8 of the 17 patients have a solid tumor sample (metastatic site); 5 (7, 2, 2, and 1) patients have 1
132 (2, 3, 4, and 5 respectively) plasma sample collected at different time points. We also collected
133 samples from 8 NSCLC patients and 4 ovarian cancer patients and generated our own WES data
134 as described below. For all 8 NSCLC patients, a tumor biopsy sample, a WBC sample, and three
135 plasma samples were collected. For all 4 ovarian cancer patients, a WBC sample and two serum
136 samples were collected. In addition, for the ovarian cancer patient OV4, who underwent surgical
137 resection at the first blood collection, we collected the patient's tumor tissue sample. For all
138 sources, only one WBC sample (or its WES data) was collected for each cancer patient.

139

140 **Human subjects**

141 We collected blood samples, tumor samples, and WBC samples from 8 NSCLC patients from
142 KEYNOTE-001 [30] and KEYNOTE-010 [31], who all provided informed consent for research use.
143 The blood and tissue collection protocols were described in the full protocol of KEYNOTE-001
144 and KEYNOTE-010. The project was approved by the Institutional Review Board (IRB) of
145 University of California, Los Angeles (IRB# 12-001891, IRB# 11-003066, and IRB# 13-00394)
146 and was conducted in accordance with the Belmont Report. We also collected samples from 4

147 ovarian cancer patients. Serum was harvested from whole blood by centrifugation (400xg, 15')
148 and immediately flash frozen. PBMCs were harvested from whole blood collected in a blue top
149 phlebotomy tube with sodium citrate, centrifuged (400xg, 15'), and aliquoted from the buffy coat
150 before being immediately flash frozen. Portions of solid tumor from the operating room were
151 brought back to the lab and flash frozen. Clinical information from consenting patients was
152 obtained from medical records. Longitudinally collected clinical specimens from ovarian cancer
153 patients were obtained using IRB-approved protocols (IRB# 10-000727) and were studied in
154 accordance with the Belmont Report. All patients provided written informed consent.

155

156 **Genomic DNA WES library construction**

157 For the 8 NSCLC patients, the WBC samples underwent multiplexed paired-end WES to a target
158 depth of 100-150x on HiSeq 2000/3000 (Illumina, San Diego, CA) performed by the UCLA
159 Technology Center for Genomics & Bioinformatics. Macrodissection was not performed. DNA
160 isolation was performed with DNeasy Blood & Tissue Kit (Qiagen, Germany); exon capture and
161 library preparation for the 8 NSCLC patients (WBC samples) used the KAPA HyperPrep Kit and
162 Nimblegen SeqCap EZ Human Exome Library v3.0 (Roche, Switzerland) before the final step of
163 2x150bp paired-end sequencing by Genewiz (South Plainfield, NJ). For the 4 ovarian cancer
164 patients, the WBC gDNA and the tumor tissue gDNA isolation were performed with DNeasy Blood
165 & Tissue Kit (Qiagen) and sonicated by Covaris system (Woburn, MA). Ampure XP beads
166 (Beckman-Coulter, Atlanta, GA) size selection was further performed to enrich the fragments
167 between 100 and 250bp. In brief, 0.9 volume of beads were first added to the fragmented gDNA
168 samples. After incubation, the supernatant was transferred to a new tube and an additional 1.1
169 volume of beads were added. After 80% ethanol wash, the size-selected gDNA was eluted from
170 the beads. The gDNA WES library was constructed with the SureSelect XT HS kit from Agilent
171 Technologies (Santa Clara, CA) according to the manufacturer's protocol. No molecular barcodes
172 were used in the sequencing libraries. In brief, 100ng of gDNA was used as input material. After

173 end repair/dA-tailing of cfDNA, the adaptor was ligated. The ligation product was purified with
174 Ampure XP beads and the adaptor-ligated library was amplified with index primer in 8-cycle PCR.
175 The amplified library was purified again with Ampure XP beads, and the amount of amplified DNA
176 was measured using the Qubit 1xdsDNA HS assay kit (ThermoFisher, Waltham, MA). 1000 ng of
177 DNA sample was hybridized to the capture library and pulled down by streptavidin-coated beads
178 (ThermoFisher). After washing the beads, the DNA library captured on the beads was re-amplified
179 with 9-cycles of PCR. The final libraries were purified by Ampure XP beads. The library
180 concentration was measured by Qubit. The library quality check was further performed with
181 Agilent Bioanalyzer before the final step of 2x150bp paired-end sequencing by Genewiz (South
182 Plainfield, NJ).

183

184 **Plasma cfDNA WES library construction**

185 For each of the 8 NSCLC patients, venipuncture was performed by trained phlebotomists such
186 as nurses or medical assistants. Blood tubes were centrifuged at 1,800g for 20 min at room
187 temperature and plasma supernatant was isolated within 2 hours of collection. Samples were
188 stored at -80°C until use. Then, cfDNA was extracted from their plasma samples using the
189 QIAamp circulating nucleic acid kit from QIAGEN (Germantown, MD). The cfDNA WES library
190 was constructed with the SureSelect XT HS kit from Agilent Technologies (Santa Clara, CA)
191 according to the manufacturer's protocol. No molecular barcodes were used in the sequencing
192 libraries. In brief, 10ng of cfDNA was used as input material. After end repair/dA-tailing of cfDNA,
193 the adaptor was ligated. The ligation product was purified with Ampure XP beads (Beckman-
194 Coulter, Atlanta, GA) and the adaptor-ligated library was amplified with index primer in 10-cycle
195 PCR. The amplified library was purified again with Ampure XP beads, and the amount of amplified
196 DNA was measured using the Qubit 1xdsDNA HS assay kit (ThermoFisher, Waltham, MA). 700-
197 1000 ng of DNA sample was hybridized to the capture library and pulled down by streptavidin-
198 coated beads. After washing the beads, the DNA library captured on the beads was re-amplified

199 with 10-cycles of PCR. The final libraries were purified by Ampure XP beads. The library
200 concentration was measured by Qubit, and the quality was further examined with Agilent
201 Bioanalyzer before the final step of 2x150bp paired-end sequencing by Genewiz (South Plainfield,
202 NJ), at an average depth of 200x.

203

204 **Serum cfDNA WES library construction**

205 For the serum samples from the four ovarian cancer patients, cfDNA was extracted by QIAamp
206 circulating nucleic acid kit (QIAGEN). Ampure XP beads size selection was further performed to
207 eliminate gDNA contamination. In brief, 0.5 volume of beads were first added to the cfDNA
208 samples. After incubation, the supernatant was transferred to a new tube and an additional 2.0
209 volume of beads were added. After 80% ethanol wash, cfDNA was eluted from the beads. FA
210 assays (Agilent Technologies) were performed to rule out the contamination of gDNA in the size
211 selected samples. The cfDNA WES library was constructed with the SureSelect XT HS kit from
212 Agilent Technologies (Santa Clara, CA) according to the manufacturer's protocol. No molecular
213 barcodes were used in the sequencing libraries. In brief, 5-20ng of gDNA was used as input
214 material. After end repair/dA-tailing of cfDNA, the adaptor was ligated. The ligation product was
215 purified with Ampure XP beads and the adaptor-ligated library was amplified with index primer in
216 11 cycles (for 10-20ng cfDNA input) or 12 cycles (for cfDNA less than 10ng). The amplified library
217 was purified again with Ampure XP beads, and the amount of amplified DNA was measured using
218 the Qubit 1xdsDNA HS assay kit (ThermoFisher, Waltham, MA). 1000 ng of DNA sample was
219 hybridized to the capture library and pulled down by streptavidin-coated beads (ThermoFisher).
220 After washing the beads, the DNA library captured on the beads was re-amplified with 9-cycles
221 of PCR. The final libraries were purified by Ampure XP beads. The library concentration was
222 measured by Qubit. The library quality check was further performed with Agilent Bioanalyzer
223 before the final step of 2x150bp paired-end sequencing by Genewiz (South Plainfield, NJ).

224

225 **Data preprocessing**

226 Both genomic DNA sequencing data and cfDNA sequencing data were preprocessed using the
227 same procedure. Raw sequencing data (FASTQ files) were aligned to the hg19 reference genome
228 by *bwa mem* [32] and sorted by *samtools* [33]. Then, duplicated reads from PCR amplification
229 were identified and removed by *picard tools MarkDuplicates* [34]. After this step, read group
230 information was added to the bam file using *picard tools AddOrReplaceReadGroups*, and reads
231 were realigned around indels using *GATK RealignerTargetCreator* and *IndelRealigner* [35][36].
232 After realignment, base quality scores were recalibrated using *GATK BaseRecalibrator* and
233 *PrintReads*. All tools in the data preprocessing pipeline were used with their default settings. After
234 data preprocessing, the resulting bam files were used as inputs for mutation detection and MRD
235 detection.

236

237 **Predicting MRD/recurrence in the post-treatment samples using somatic mutations** 238 **detected from the pre-treatment samples**

239 We predict the presence of MRD/recurrence by tracking the cfDNA fragments containing tumor-
240 derived somatic mutations (i.e., tumor-derived cfDNA fragments). Due to the low tumor fraction in
241 the plasma samples from patients with MRD, we integrate all clonal mutations in the exome to
242 enhance the tumor signal (see **Identification of clonal mutations in pre-treatment samples**,
243 Figure 1b (1)). To limit the accumulation of sequencing errors during integration, we employ a
244 machine learning model (see **Machine learning model for suppressing sequencing errors**,
245 Figure 1b (2)) that can accurately distinguish reads with sequencing errors from true mutations.
246 Then, the level of tumor-derived cfDNA fragments is compared with a background noise
247 distribution generated from the same plasma sample by a permutation test (see **Identification of**
248 **mutations and CHIP positions** and **Building background noise distribution using random**
249 **genomic locations**, Figure 1b (3)). If the tumor-derived cfDNA fragments are significantly more
250 abundant than the background noise in the sample (p -value ≤ 0.05), the patient is predicted as

251 having MRD/recurrence. If no MRD/recurrence is detected, the post-treatment sample is
252 subsequently examined for the presence of second primary cancers (see **Detection of a second**
253 **primary cancer**, Figure 1b (4)).

254

255 **Calculation of the Integrated Variant Allele Frequency (IVAF)**

256 To quantify tumor DNA across multiple loci, we calculate the Integrated Variant Allele Frequency
257 (IVAF) as the number of sequencing read pairs classified by the model as containing true
258 mutations divided by the total number of read pairs. Both the numerator and the denominator are
259 summed over all loci identified as clonal mutations in the pre-treatment sample. The IVAF
260 indicates the fraction of high-confidence tumor DNA in all cfDNA fragments, so it is treated as the
261 estimated tumor fraction in this study.

262

263 **Identification of clonal mutations in pre-treatment samples**

264 The presence of tumor-derived somatic mutations in cfDNA is usually treated as a reliable marker
265 to confirm the presence of cancer. However, not all tumor-derived somatic mutations are equally
266 effective, because subclonal mutations have a lower observed allele frequency than clonal
267 mutations [5]. To overcome the challenge of low tumor content in the plasma samples of patients
268 with MRD, we integrate tumor-derived somatic mutations over a wide range of the genome (e.g.,
269 the whole exome data obtained by WES). The integration accumulates not only tumor-derived
270 signals but also sequencing errors. Therefore, we used clonal somatic mutations, called from the
271 pre-treatment plasma sample or the pre-treatment tumor sample, as tumor markers. To make this
272 selection, first tumor-derived somatic mutations are detected using *cfSNV* [12] from the pre-
273 treatment plasma sample; if only the pre-treatment tumor sample is available, tumor-derived
274 mutations are the common mutations detected by Strelka2 [37] somatic and MuTect [38] from the
275 pre-treatment tumor sample. The detected mutations are removed if there is at least one variant
276 supporting read in the matched WBC sample. A mutation is considered clonal, and hence retained

277 in the final marker list, if its VAF is $> 25\%$ of the average of the five highest VAFs in the sample
278 [39]. We require a minimum of 30 markers from the pre-treatment plasma sample to obtain a
279 robust prediction. If there are fewer than 30 clonal mutations, subclonal mutations with the highest
280 VAFs will be included.

281
282 **Identification of mutations and Clonal Hematopoiesis of Indeterminate Potential (CHIP)**
283 **positions**

284 To accurately estimate the background noise in a sequencing experiment, it is essential to remove
285 the interference from non-reference alleles at the germline mutations, somatic mutations, and
286 CHIP positions. To estimate the background, we identify germline mutations in the pre-treatment
287 plasma sample and the matched WBC sample from the same patient using *GATK HaplotypeCaller*
288 *HaplotypeCaller* and *Strelka2 Germline* with the default settings. *GATK HaplotypeCaller* is applied
289 to the plasma sample and the WBC sample individually; *Strelka2 Germline* is applied to the
290 plasma-WBC sample pair. Somatic mutations are detected in the plasma sample and the matched
291 WBC sample using *cfSNV* under default settings. The CHIP positions are identified from pileup
292 files generated using *samtools mpileup*. If a non-mutated position has ≥ 3 variant supporting
293 reads or a VAF $> 1\%$ in the matched WBC sample, it is regarded as a CHIP position. The selection
294 of these parameters has little impact on the performance (Supplementary Figure 4a-b). All the
295 identified germline mutations, somatic mutations and CHIP positions are excluded in the step of
296 building the background noise distribution.

297
298 **Building a background noise distribution using random genomic locations**

299 The simple presence of variant supporting reads at tumor-derived somatic mutations is not
300 enough to determine the presence of MRD/recurrence, because they could be caused by
301 sequencing errors. Therefore, to quantify the sequencing error frequency, we build a background
302 noise distribution from the same plasma sample that we use to monitor MRD/recurrence. Unlike

303 using a panel of normal samples from other sources, this approach avoids potential biases from
304 inter-individual and inter-experimental differences. A background noise distribution is generated
305 for the clonal tumor mutations that were identified from the pre-treatment sample for
306 MRD/recurrence monitoring. For a set of n clonal tumor mutations, n positions are randomly
307 selected from the targeted genomic region (e.g., the whole exome), excluding known mutations
308 and CHIP positions. Ideally, all read pairs with non-reference alleles at these n positions are from
309 sequencing errors, so the observed frequency of these reads represents the background noise
310 level. The sequencing read pairs containing non-reference alleles at these n positions are
311 extracted and input into the sequencing noise suppression model. The observed frequency of a
312 non-reference allele (i.e., its integrated variant allele frequency) is calculated as the number of
313 sequencing read pairs classified by the model as containing true mutations, divided by the total
314 number of read pairs aligned to the n positions. We repeat the random sampling of n positions
315 and calculate the observed frequency of non-reference alleles K times. Finally, the background
316 noise distribution is built from the K observed frequencies of non-reference alleles at random n
317 positions. By comparing the tumor fraction θ at the clonal mutations with the background noise
318 distribution, an empirical p -value can be calculated as the rank of θ among the K background
319 IVAFs (in a decreasing order). If the empirical p -value is ≤ 0.05 , the patient is regarded as having
320 MRD/recurrence. Based on our simulation, only minor differences in the detection threshold occur
321 when K is set to 100, 500, or 1000. Therefore, in our simulation, we set K to 100.

322

323 **Machine learning model for suppressing sequencing errors**

324 Although weak tumor signals in plasma samples can be amplified by integrating the variant
325 supporting reads across a large genomic region, sequencing errors can also accumulate and
326 possibly confound the tumor signal. Moreover, because of the low fraction of tumor DNA, the
327 variant supporting reads at a single mutation are not sufficient to provide a robust and accurate

328 estimation of site-level statistics (e.g., strand bias and average base quality) for error removal.
329 Therefore, we developed a machine learning filter to eliminate reads with sequencing errors
330 (Supplementary Figure 5). Specifically, for a group of genomic positions (tumor mutations or
331 random positions), we classify the variant supporting reads with a random forest model to
332 distinguish sequencing errors from true variants. Since all data in this study were generated from
333 paired-end sequencing, in the following section, we detail the model for paired-end reads, but the
334 principle can also be applied to single-end reads. With paired-end sequencing data, there are two
335 types of read pairs with regards to a specific mutation site: one (non-overlapping read pair) covers
336 the mutation site by one of its read mates, the other (overlapping read pair) covers the mutation
337 site by both of its read mates (Supplementary Figure 5a). The overlapping read pair can provide
338 two readouts of the mutation site on the DNA fragment in the sequencing library, but the non-
339 overlapping read pair can only provide one readout. This means that the overlapping read pair
340 naturally contains more information about the mutation site than the non-overlapping read pair,
341 and the two readouts can serve as validation for each other. Therefore, we trained two
342 independent random forest models to fully utilize the information in the non-overlapping read pair
343 and the overlapping read pair. Please note that the random forest models in *cfTrack* classify
344 sequencing errors and true variants in every read pair, i.e. read-level error suppression. It is
345 different from the empirical variant score model in Strelka and the variant quality score model in
346 GATK, which rely on site-level statistics (such as averaged base quality in all reads) to classify
347 sequencing errors and true variants.

348
349 To train the random forest model, we used WES data from 18 patients: 12 with metastatic breast
350 cancer (MBC) and 6 with metastatic prostate cancer (CRPC) [17](Supplementary Figure 5b).
351 Each patient had four samples sequenced: two plasma samples (collected at two different time
352 points), a WBC sample, and a tumor biopsy sample. We use the supporting cfDNA read pairs at
353 known mutation (error) sites as the training data. The known mutation sites include both germline

354 and somatic mutation sites, where germline mutations are required to be detected in all four
355 samples using *Strelka2 germline*, and somatic mutations are required to be detected from both
356 the cfDNA-WBC pairs (cfDNA data vs. WBC data) and the tumor-WBC pair (tumor data vs. WBC
357 data) using *Strelka2 somatic* and *MuTect*. Error sites are defined as sufficiently covered sites (>
358 150x) with at most two high-quality non-reference read (base quality ≥ 20 and mapping quality \geq
359 40) in only one of the four datasets. All high-quality labeled read pairs (base quality ≥ 30 and
360 mapping quality ≥ 40) were extracted from raw cfDNA data using *picard tools FilterSamReads*.
361 Multiple read pairs may be extracted covering the same mutation site, but these read pairs are
362 similar and might cause redundancy in the training and testing data. Therefore, we solved the
363 redundancy problem by retaining only one read pair per mutation/error site (Supplementary Table
364 4). Different features were extracted from the overlapping read pairs and the non-overlapping
365 read pairs (Supplementary Table 1). All categorical features were expanded using the one-hot
366 encoding method. The hyper-parameters of the random forest model were as follows: (1) the
367 number of decision trees was 100, (2) the maximum tree depth was 50, (3) imbalanced classes
368 were addressed by setting the class weights to “balanced”, and (4) other parameters were left at
369 their default values. Two separate random forest classifiers (one for overlapping read pairs and
370 one for non-overlapping read pairs) were trained on the extracted read pairs.

371
372 We validated the performance of the random forest model by cross-validation. For each patient,
373 the labeled read pairs from the 17 other patients were used to train the model, while the patient’s
374 own data were used to test the model (results shown in Supplementary Figure 6). The training
375 data of the random forest model in all the simulation (MRD/recurrence and second primary
376 cancers) also exclude the patient used for generating the simulation data to avoid data leakage.
377 Therefore, the evaluation of *cfTrack* is independent of the training data. As an independent
378 validation set, we used a group of non-small-cell lung cancer patients (8 patients each with 3
379 samples) with sequential plasma cfDNA samples. The read pairs in these cfDNA samples were

380 labeled in the same manner as described above. Then, these labeled read pairs were used as
381 independent testing data for the random forest model trained by the data generated from the 12
382 MBC and 6 CRPC patients. On all cross-validation datasets, the random forest model can
383 accurately distinguish sequencing errors from true variants (average AUC = 0.95, 95% confidence
384 interval (CI) = 0.9496-0.9503).

385
386 **Simulation of recurrence and MRD detection by tracking clonal somatic mutations in pre-**
387 **treatment samples**

388 To evaluate the performance of our method, we generated simulation data to mimic patients with
389 MRD/recurrence and patients with complete remission. The patients with MRD/recurrence have
390 tumor content in the post-treatment plasma sample and will show the detection sensitivity; the
391 patients with complete remission have no tumor content in the post-treatment plasma sample and
392 will show the detection specificity. The simulation data were generated from two datasets
393 independently: (1) validation dataset, 27 MBC and 14 CRPC patients and (2) independent dataset,
394 8 NSCLC patients.

395
396 In the validation dataset, only 12 MBC and 6 CRPC patients have two plasma cfDNA samples,
397 so only these patients were used to generate the post-treatment cfDNA samples from the
398 MRD/recurrence patients. Note that these data were also used to generate the training data for
399 the read-level error suppression model. Therefore, to avoid data leakage in the performance
400 evaluation, the MRD/recurrence detection on the validation dataset was performed in a “leave-
401 one-patient-out cross-validation” manner. In other words, for a simulated sample (generated from
402 WES data from a specific patient) in the validation dataset, the random forest models used in the
403 error suppression step were trained on the other 17 patients. In the independent dataset, the 8
404 NSCLC patients have three plasma cfDNA samples. Only the first two time points of the plasma
405 cfDNA samples were used in the simulation. These data were untouched and independent of the

406 training of the read-level error suppression model, so the error suppression model used on the
407 independent dataset was trained by all training data extracted from the 12 MBC and 6 CRPC
408 patients.

409
410 To demonstrate the sensitivity of detection for pre-existing cancer, we generated *in silico* dilution
411 series to simulate patients with MRD/recurrence by mixing the plasma sample collected at the
412 second time point and the matched WBC sample at varying concentrations of cfDNA reads
413 (0.01%, 0.05%, 0.1%, 0.3%, 0.5%, 0.8%, 1%, 3%, 5%, and 8%) using *samtools view* and
414 *samtools merge*. Five independent mixtures were generated at every concentration, at theoretical
415 depths of 200x, 100x or 50x on the WES targeted regions. Since read sampling is random, it is
416 possible that there is no variant supporting read at a given marker, even across all markers. Thus,
417 we removed samples with no variant supporting reads at all personalized markers (checked by
418 *samtools mpileup*). In this simulation, the original matched WBC samples and the original plasma
419 samples at the first time point were used as the WBC samples and the pre-treatment plasma
420 samples, respectively (Figure 2). The *in silico* dilution series represents post-treatment plasma
421 samples from patients with MRD/recurrence. For the validation dataset, we generated the data
422 for each of the 12 MBC and 6 CRPC patients. The theoretical tumor fraction in each sample is
423 calculated as the product of the original tumor fraction in the cfDNA sample and the dilution. The
424 theoretical tumor fraction ranges from 0.001% to 6.114%, with a median of 0.270%. For the
425 independent dataset, we generated the data for each of the 8 NSCLC patients. The theoretical
426 tumor fraction ranges from 0.001% to 1.867%, with a median of 0.103%. The different ranges of
427 the theoretical tumor fractions in the two datasets are caused by differences in the tumor content
428 levels in the original plasma samples. Note that the theoretical tumor fraction usually
429 overestimates the true tumor fraction because of random sampling and the imperfect on-target
430 rate.

431

432 To evaluate the specificity of the MRD detection pipeline, we generated the patients with complete
433 remission by subsampling from the original WBC samples. Therefore, these subsamples are
434 expected to have no tumor DNA. For a WBC sample from a cancer patient, five subsamples were
435 generated for each of 200x, 100x, and 50x theoretical depth of the targeted regions. These
436 subsamples represent post-treatment plasma samples from patients without MRD. The original
437 plasma samples at the first time point were used as the pre-treatment plasma samples. Note that
438 only one WBC sample was available for each patient. If the only original WBC sample was directly
439 used as the pre-treatment WBC sample, all data in the post-treatment plasma samples (i.e.
440 subsamples) would have been observed in the pre-treatment WBC sample (i.e. the full original
441 sample), which is impossible in reality. Therefore, we used another subsample of the original
442 WBC samples as the pre-treatment data at a sampling rate of 95% (Figure 2). In this simulation,
443 we preserved some randomness between the WBC samples and the post-treatment plasma
444 samples, which reflects real cases. For the validation dataset, we generated the remission
445 samples for each of the 27 MBC and 14 CRPC patients. For the independent dataset, we
446 generated the remission samples for each of the 8 NSCLC patients.

447
448 To avoid potential bias from independently sampling replicates from the same patients, we
449 randomly selected 1 replicate at every dilution (including 0% for remission samples) for every
450 patient to calculate the performance (AUC, sensitivity, and specificity). After the selection, the
451 performance metrics (AUC, sensitivity, and specificity) were evaluated on the MRD/recurrence
452 samples grouped by the tumor fraction with a 0.01% step size and the remission samples
453 (samples with WBC reads only). To provide a robust estimate, we randomly selected samples
454 and calculated the performance 50 times. For the validation dataset, in each random selection,
455 there are 41 simulated remission samples at each depth. At 200x, there are 143 simulated
456 MRD/recurrence samples; at 100x, there are 142 simulated MRD/recurrence samples; at 50x,
457 there are 128 simulated MRD/recurrence samples. For the independent dataset, in each random

458 selection, there are 8 simulated remission samples at each depth. At 200x, there are 68 simulated
459 MRD/recurrence samples; at 100x, there are 65 simulated MRD/recurrence samples; at 50x,
460 there are 56 simulated MRD/recurrence samples.

461

462 **Detection of a second primary cancer**

463 A second primary cancer is detected based on a logistic regression model, whose features are
464 the tumor fraction and the number of detected mutations from *cfSNV* in the post-treatment plasma
465 samples. A sample is predicted with second primary cancers if its prediction score is larger than
466 95% percentile of prediction scores from the remission samples in the training data; otherwise, it
467 is predicted as remission.

468

469 **Simulation of second primary cancer detection**

470 Similar to the simulation of recurrence and MRD detection, to evaluate the sensitivity of the
471 method for second primary cancer detection, we generated an *in silico* dilution series by mixing
472 the plasma samples at the second time point and the matched WBC samples from the 12 MBC
473 and 6 CRPC patients at varying concentrations of cfDNA reads (from 1% to 10%: 1%, 3%, 5%,
474 8%, and 10%) using *samtools view* and *samtools merge*. Since no training and testing of new
475 models is performed in the detection of second primary cancers, this is an independent testing
476 dataset with respect to the detection method. Each spike-in sample contained a total number of
477 randomly sampled reads theoretically equivalent to 200x depth of the targeted regions. Five
478 independent mixtures were generated at every concentration. The tumor fraction in these spike-
479 in samples was quantified by the variant supporting reads at the clonal somatic mutations
480 identified in the original plasma sample. In this simulation, the original matched WBC samples
481 were used as the WBC samples. To demonstrate the specificity of the method, we reused the
482 complete remission samples at 200x generated in the simulation of recurrence and MRD
483 detection. To avoid potential bias from independently sampling replicates from the same patients,

484 we randomly selected 1 replicate at every dilution for every patient to calculate the performance
485 (AUC, sensitivity, and specificity). To provide a robust estimate, we randomly selected samples
486 and calculated the performance 10 times. In each random selection, there were 90 simulated
487 samples from patients with second primary disease and 41 simulated samples from patients with
488 complete remission. To evaluate the performance, after removing the replicates, the simulation
489 data were randomly split into the training set (50%, $n = 66$) and the testing set (50%, $n = 65$) ten
490 times. A logistic regression model is trained on the training set and used to predict the presence
491 of a second primary cancer in the testing set. The performance metrics (AUC, sensitivity, and
492 specificity) are evaluated in the testing set on the second primary cancer samples grouped by
493 tumor fraction with a 0.1% step size, but always using the complete set of remission samples.

494

495

496 **Results**

497

498 **Comprehensive and personalized cancer monitoring using cfDNA.**

499

500 We present a new cancer monitoring method (Figure 1a and Figure 1b), *cfTrack*, that analyzes
501 both pre-existing tumor mutations and newly emerging mutations in post-treatment samples. We
502 developed four major techniques to suppress background noise, generate sample-specific
503 background noise distributions, and achieve comprehensive and sensitive detection of tumor-
504 derived cfDNA. Specifically, we collect a plasma or solid tumor sample and a matched white blood
505 cell (WBC) sample from a patient before the treatment to select markers (i.e., mutations) that are
506 specific to the pre-existing tumor. In the post-treatment plasma samples, *cfTrack* both tracks pre-
507 existing tumor markers and detects new somatic mutations. The techniques in *cfTrack* are
508 summarized below.

509 **(1) Integrate all clonal tumor mutations from the pre-treatment samples.** Tumor mutations
510 evolve, so any given somatic mutation observed in pre-treatment samples may disappear in post-
511 treatment samples. We perform WES of the pre-treatment samples (solid tumor or plasma
512 samples) and select clonal somatic mutations that appear in all pre-existing cancer cells and have
513 high variant allele frequencies (VAFs) in the cfDNA [4]. Compared to a pre-defined, limited panel
514 of known tumor mutations, the clonal mutations of this specific patient, observed in WES, are
515 more likely to appear in post-treatment samples and are more informative for monitoring the pre-
516 existing tumor [5]. However, when the tumor fraction in cfDNA is very low, WES sequencing at
517 medium depth (100x or 200x) may contain few variant supporting reads at a specific locus.
518 Therefore, to provide a robust mutation-based statistic index in cfDNA, *cfTrack* aggregates variant
519 supporting reads across all clonal somatic mutations (for details, see Methods and Supplementary
520 Figure 1a-b). Specifically, we quantify the tumor fraction using the integrated variant allele
521 frequency (**IVAF**), which is the sum of variant supporting reads divided by the sum of all reads at
522 the clonal somatic mutations. Note that a recent publication developed a similar integrative
523 approach using the reads from whole-genome sequencing of cfDNA [11]. Here we show that WES
524 of cfDNA can also be used for ultra-sensitive cancer detection, and given its cost-effectiveness
525 compared to WGS it is more feasible for clinical use.

526 **(2) Suppress sequencing errors at the read level with a random forest model.** When we
527 integrate tumor reads across a large number of mutation sites to amplify the tumor signal,
528 sequencing errors also accumulate. Therefore, we have developed a method to suppress
529 individual sequencing errors and enhance the signal-to-noise ratio of cancer detection by
530 differentiating the reads containing sequencing errors from those containing true variants.
531 Specifically, this filter is based on a random forest model (for details, see Methods). Previous work
532 has shown that it is possible for machine learning to distinguish true cancer mutations from
533 sequencing artifacts at the read level, and such filters have been used to predict mutations and
534 detect cancer and MRD [11][13]. Unlike these previous works, our method is specifically designed

535 for cfDNA WES data: it incorporates cfDNA fragmentation patterns and read sequence contexts
536 (e.g. nucleotide substitution C>A). Both features are informative to distinguish tumor-derived true
537 mutations and sequencing errors: tumor-derived cfDNA fragments are shorter than non-tumor-
538 derived cfDNA fragments [14][15]; sequencing error rates are associated with nucleotide
539 substitution types [16]. By combining a wide variety of features (Supplementary Table 1), our
540 model automatically discovers feature co-occurrence relationships that are associated with
541 sequencing errors. The random forest model classifies all supporting reads at clonal somatic
542 mutation loci as containing either a true variant or a sequencing error. Only those reads classified
543 as “true variants” are counted as variant supporting reads.


544 **(3) Predict recurrence or MRD using sample-specific background noise distribution.** To
545 predict whether a patient has recurrence or MRD, we need to compare the estimated tumor
546 fraction with a background noise distribution which represents the error allele fraction in samples
547 from individuals without a tumor. Previous studies usually compared the post-treatment sample
548 of a patient with a cohort of samples from healthy individuals. Because the inter-individual and
549 inter-experimental differences are difficult to model, however, this kind of comparison can
550 introduce prediction bias, and the resulting detection thresholds are difficult to generalize to other
551 experimental protocols. To avoid this limitation, we build the background noise distribution by
552 calculating the IVAF from random genomic positions *in the same sample* (Figure 1b; for details,
553 see Methods). Therefore, this background noise distribution represents the actual error rates
554 observed in this specific sequencing experiment. Recurrence or MRD can then be detected using
555 the empirical p -value of the tumor fraction calculated from the pre-existing clonal mutations with
556 respect to the sample-specific background noise distribution (for details, see Methods).

557 **(4) Detect tumor evolution by *de novo* identifying newly emerging tumor mutations.**
558 Previously described methods for cancer monitoring focus on a predefined mutation panel, which
559 makes it difficult to detect tumor evolution or second primary cancers. Taking advantage of the
560 WES data with broad genome coverage, *cfTrack* performs *de novo* mutation identification to

561 accomplish both. For this we utilize *cfSNV* [12], a method we recently developed for the sensitive
562 and accurate calling of somatic mutations in plasma samples. *cfSNV* specifically accommodates
563 key cfDNA-specific properties, including the low tumor fraction, short and non-randomly
564 fragmented DNA, and heterogeneous tumor content. It addresses the low tumor fraction and
565 tumor heterogeneity in cfDNA by iterative and hierarchical mutation profiling, and ensures a low
566 false-positive rate by multilayer error suppression. Based on the mutation calling results from
567 cfDNA, we can directly detect tumor evolution or the presence of second primary cancers in terms
568 of *de novo* mutations and the corresponding tumor fraction aggregated across mutation sites (for
569 details, see Methods).

570

571



572

573 **Figure 1. Cancer monitoring in plasma samples by tracking pre-existing tumor mutations and newly emerging**

574 **tumor mutations. (a)** Illustration of the sample collection for cfDNA-based cancer monitoring. Prior to surgery or

575 therapy, a plasma or tumor sample and a white blood cell (WBC) sample are collected to generate the pre-existing

576 tumor profile. Serial blood samples are collected to detect MRD/recurrence and monitor tumor evolution after

577 treatment. **(b)** Illustration of the method workflow. In the pre-treatment samples, clonal tumor mutations are identified

578 for tumor tracking in the post-treatment samples. Given a post-treatment plasma sample, the tumor fraction is
579 calculated from the pre-existing clonal tumor mutations and compared to a sample-specific background distribution.
580 The empirical p-value of the tumor fraction is used to predict MRD/recurrence. Furthermore, *de novo* somatic
581 mutations are detected using *cfSNV* between the post-treatment plasma and WBC samples. A second primary cancer
582 is predicted by a logistic regression model that accounts for both the amount of *de novo* mutations and the
583 corresponding tumor fraction.

584

585

586 **Analytical performance of detecting cancer recurrence and MRD.**

587


588 To evaluate the performance of *cfTrack* on cancer MRD or recurrence, we use the *in silico* method
589 of preparing spike-in simulation data. If a cancer patient has cancer recurrence or MRD, the post-
590 treatment plasma of the patient will contain DNA corresponding to the pre-existing tumor. To
591 simulate the post-treatment plasma samples from the patients with cancer recurrence or MRD,
592 we computationally mix a plasma sample from a cancer patient with a WBC sample from the
593 same patient. The data, with known dilution ratios, can provide a sensitivity/specificity assessment
594 on *cfTrack*.

595

596 We generated two sets of *in silico* spike-in simulation data (see Methods): (1) validation dataset,
597 using the WES data from 12 patients with metastatic breast cancer (MBC) and 6 patients with
598 metastatic prostate cancer (castrate-resistant prostate cancer, CRPC) [17] and (2) independent
599 dataset, using the WES data from 8 patients with non-small cell lung cancer (NSCLC). For both
600 datasets, each patient has sequencing data from two plasma samples (collected at two different
601 time points T_1 and T_2 , with 14~138 days in between for MBC and CRPC patients, 42 days in
602 between for NSCLC patients), and the matched WBC sample. These patients underwent
603 treatment between T_1 and T_2 , so we consider the first plasma samples (at T_1) the “pre-treatment”

604 samples, and the second plasma samples (at T_2) the “post-treatment” samples. Tens to hundreds
 605 of clonal somatic mutations (for MBC and CRPC patients, ranging from 49 to 674 with median 94;
 606 for NSCLC patients, ranging from 30 to 1239 with median 63) are found in the pre-treatment
 607 samples when compared to their matched WBC samples. We then generate an *in silico* dilution
 608 series for each patient by mixing their post-treatment plasma sample with the matched WBC
 609 sample at varying fractions (the theoretical tumor fraction ranges from 0.001% to 6.114% with
 610 median 0.270% for the validation dataset, from 0.001% to 1.867% with median 0.103% for the
 611 independent dataset; for details, see Methods and Figure 2). In addition, we simulate patients
 612 who achieved complete remission by subsampling the original WBC samples (the tumor fraction
 613 is 0%, for details see Methods and Figure 2). The simulation data are generated at three different
 614 depths, 50x, 100x and 200x.

615
 616




617
 618 **Figure 2. Settings to generate *in silico* spike-in simulation data.** The simulation data are generated using WES data
 619 taken from (1) 12 MBC and 6 CRPC patients and (2) 8 NSCLC patients. Each patient has an early plasma sample
 620 (Blood T_1), a WBC sample (WBC), and a late plasma sample (Blood T_2). The three WES datasets from a patient are

621 used directly or mixed to generate the simulation samples. To simulate the scenario of monitoring a patient for MRD
622 or cancer recurrence, each case contains three simulation samples: a pre-treatment plasma sample, a pre-treatment
623 WBC sample, and a post-treatment plasma sample. The raw data from Blood T₁ are used directly as the pre-treatment
624 plasma sample for all cases. WBC and Blood T₂ are mixed at specified dilutions to simulate the post-treatment plasma
625 sample. To simulate remission cases, we generate two independent random samplings from the raw WBC data to use
626 as the pre-treatment WBC sample and the post-treatment plasma sample. To simulate the emergence of second primary
627 cancers, each case contains two simulation samples: a pre-treatment WBC sample and a post-treatment plasma sample.
628 The generation of simulation samples for second primary cancer monitoring is the same as for MRD/recurrence
629 monitoring, except that the pre-treatment plasma sample (Blood T₁) is not used.

630
631 When applying *cfTrack* to the simulated datasets, we observe slightly increased detection
632 performance with increasing sequencing depth (Figure 3a-d and Supplementary Figure 2a-d).
633 This trend is expected because the higher the sequencing depth, the more tumor DNA fragments
634 can be captured. Specifically, on the validation dataset, we achieve an average AUC of 99%
635 (standard deviation (SD) = 1%) when the tumor fraction is $\geq 0.05\%$ at 200x depth (Figure 3a and
636 Supplementary Figure 2a), with 100% average sensitivity (SD = 0%) and 96% average specificity
637 (SD = 1%, Figure 3b and Supplementary Figure 2b). On the independent dataset, we achieve an
638 average AUC of 100% (SD = 0%) when the tumor fraction is $\geq 0.05\%$ at 200x depth (Figure 3c
639 and Supplementary Figure 2c), with 89% average sensitivity (SD = 13%) and 100% average
640 specificity (SD = 0%, Figure 3d and Supplementary Figure 2d). Considering the difference in the
641 sample size and the higher specificity in the independent dataset, the performance on the two
642 simulation datasets is comparable. This indicates that our method can achieve sensitive
643 monitoring using only 200x WES data, offering a cost-effective solution for MRD detection. The
644 detection limit can be further enhanced by increasing the sequencing depth.

645



646
 647 **Figure 3. Performance of cancer recurrence and MRD detection using the simulation data.** The area under the
 648 ROC curve (AUC) of the MRD/recurrence detection on (a) the validation dataset and (c) the independent dataset with
 649 different tumor fractions and sequencing depths. The sensitivity and specificity with different tumor fractions and
 650 sequencing depth on (b) the validation dataset and (d) the independent dataset. Supplementary Figure 2 (a-d) is the
 651 zoom-in of (a-d) at low tumor fraction ranging from 0% to 0.2%. (e) AUCs of MRD/recurrence detection with and
 652 without error suppression (ES) on the validation dataset at 200x depth with different tumor fractions. (f) The sensitivity
 653 and specificity of MRD/recurrence detection with and without error suppression on the validation dataset at 200x
 654 depth with different tumor fractions. In (a), (c) and (e), the dots indicate the average AUC, and the vertical bars
 655 indicate average \pm SD of the AUC (see Methods). In (b), (d) and (f), the dots show the average sensitivity using a
 656 cutoff p-value = 0.05 for the background noise distribution; the vertical bars indicate average \pm SD of the sensitivity;
 657 the specificity is shown in the legend in the format of (average specificity, (average - SD, average - SD)). The solid
 658 lines show the smoothed performance fitted with logit functions.

659

660

661 Our method can achieve the high detection power thanks to three key features: the exome-wide
662 integration of tumor signals, the sample-specific decision threshold, and the read-level error
663 suppression. Read-level error suppression greatly improves the detection power, especially in
664 samples with a low tumor fraction. For example, based on our *in silico* samples with a 0.05%
665 tumor fraction, employing read-level error suppression improved AUC by 35% on the validation
666 dataset (see Figure 3e and 3f) and improved AUC by 40% on the independent dataset (see
667 Supplementary Figure 2e and 2f).

668

669 **Analytical performance of detecting second primary cancers.**

670

671 Sensitive monitoring of tumor evolution and newly emerging tumors requires the *de novo*
672 detection of mutations from previously unobserved tumors. Pre-treatment plasma samples and
673 tumor biopsy samples cannot provide sufficient tumor markers for this purpose. In contrast with
674 previous cancer monitoring methods, we can detect *de novo* tumor-derived SNVs in the post-
675 treatment plasma samples, which allows us to identify mutations that come from new tumors. In
676 this section, we specifically evaluate *cfTrack* for the detection of second primary cancers, which
677 depends solely on the detection of emerging tumors.

678


679 Detecting a second primary cancer is equivalent to detecting a new tumor without prior knowledge.
680 To simulate this scenario, we generate an *in silico* dilution series from the 12 MBC and 6 CRPC
681 patients by mixing their post-treatment plasma samples with the matched WBC samples [17]. The
682 mixed samples are prepared at varying fractions (the theoretical tumor fraction ranges from 0.111%
683 to 7.680%, with a median of 2.984%; for details, see Methods and Figure 2). For each dilution
684 level, simulation data are generated with a depth of 200x. The samples simulating complete
685 remission are the same as those used for MRD/recurrence detection (in the previous section).
686 Since the detection of a second primary cancer involves no training or testing of new models, this

687 simulation dataset is an independent dataset with respect to the detection method. In this
688 simulation, we do not use the pre-treatment plasma samples, representing the scenario where no
689 pre-existing tumor profile has been observed.

690

691 For each pair of simulated plasma and simulated WBC samples, we use *cfSNV* to identify somatic
692 mutations. Then *cfSNV* estimates a tumor fraction from these mutations. We predict a second
693 primary cancer by a logistic regression model using both the tumor fraction and the number of
694 detected mutations as features. We randomly split the samples into a training set (50%) and a
695 testing set (50%). A patient is predicted to have a second primary cancer if they have a large
696 prediction score (\geq 95th percentile of prediction scores from the remission samples in the training
697 set). The AUC is calculated based on the prediction results in the testing sets for all complete
698 remission samples and for the subset of simulation samples with a specific tumor fraction (see
699 Methods). We achieve an average AUC of 88% (SD = 10%) when tumor fraction \geq 0.2% at 200x
700 depth (Figure 4a), with an average sensitivity of 76% (SD = 23%) and an average specificity of
701 93% (SD = 5%, Figure 4b). The sensitivity of the methodology is lower for detecting second
702 primary cancers than for detecting recurrence and MRD, because no pre-existing tumor
703 information is available and all novel somatic mutations need to be confirmed. The detection of a
704 novel somatic mutation requires more variant supporting reads than just observing a weak signal
705 at a known locus. Nevertheless, *cfTrack* still achieves high performance in detecting a new tumor.
706 Therefore, *cfTrack* can be used for monitoring tumor evolution and detecting second primary
707 cancers and cancer progression.

708



709
710 **Figure 4. Performance of second primary cancer detection with the simulation data. (a)** AUC of the *in silico*
711 spike-in samples with different tumor fractions at 200x sequencing depth. The dots indicate the average AUC, and the
712 vertical bars indicate average \pm SD of the AUC (see Methods). **(b)** The sensitivity and specificity in the *in silico* spike-
713 in samples with different tumor fractions at 200x sequencing depth. The dots show the average sensitivity using a
714 cutoff of the 95th percentile of prediction scores from the remission samples in the training data; the vertical bars
715 indicate average \pm SD of the sensitivity; the specificity is shown in the text in the format of (average specificity,
716 (average - SD, average + SD)). The solid lines show the smoothed performance fitted with a logit function.

717
718 **Monitoring tumors in cancer patients on treatments through cfDNA.**

719
720 Developments in immunotherapy and targeted therapy have improved the outcomes of cancer
721 patients in recent years [18][19][20]. For example, immunotherapy, which activates a patient's
722 own immune system to fight cancer, has remarkably improved clinical outcomes in a subset of
723 NSCLC patients [21]. Despite these results, the majority of patients eventually develop resistance
724 and fail to respond to treatment [22][23][24]. Therefore, it is essential to closely monitor the
725 response of patients and quickly recognize when the need for alternative treatment arises.
726 However, since the development of resistance may be associated with tumor evolution [25], this
727 type of monitoring cannot only rely on markers derived from the pre-existing tumor, but requires

728 constant re-evaluation of the tumor profile during treatment. Our WES-based method, which
729 detects mutations from both pre-treatment and treated samples, can comprehensively track a
730 patient's response.

731
732 To test our method in this clinical scenario, we applied our cancer monitoring method to
733 plasma/serum samples (n = 76, 8 serum samples for 4 ovarian cancer patients and 68 plasma
734 samples for other patients) from a cohort of cancer patients (n = 35) who received various
735 treatments. This cohort contains 18 prostate cancer patients [26][27], 8 lung cancer patients, 4
736 ovarian cancer patients, 3 glioma patients, 1 bladder cancer patient [27], and 1 germ cell cancer
737 patient [27]. All plasma/serum samples were collected when the patients didn't have complete
738 remission or had recurrence, so tumor content was expected in all samples. After applying our
739 method, tumor-derived DNA was detected in all cfDNA samples except three plasma samples
740 from glioma patients (Supplementary Figure 3). Because the detection of tumor-derived cfDNA is
741 only possible in a very small fraction of glioma patients due to the blood-brain barrier [28], our
742 results were reasonable and consistent with the literature.

743
744 Among the 35 patients, 8 NSCLC patients, 4 ovarian cancer patients and 12 prostate cancer
745 patients have at least two plasma/serum samples collected at different time points, between which
746 the patients received treatments. To monitor the tumor changes in these patients, two tumor
747 fractions are calculated separately for the pre-existing tumor mutations (pre-existing tumor
748 fraction) and for the *de novo* tumor mutations (*de novo* tumor fraction) from *cfTrack*. The two
749 tumor fractions allow us to track possible tumor mutations during treatment.

750
751 The eight NSCLC patients received anti-PD-1 immunotherapy and their plasma samples were
752 collected from each patient at 0 weeks (baseline), 6 weeks and 12 weeks, measured from the
753 start of treatment. Among these patients, four are "durable responders" whose progression-free

754 survival (PFS) is longer than 18 months; the other four patients are “early progressors” whose
755 PFS is shorter than 6 months (see Supplementary Table 2). In general, we observe a decreasing
756 or low tumor fraction in the durable responders and an elevated tumor fraction in the early
757 progressors (Figure 5a). An unusual example in the sample is early progressor LC-2, whose pre-
758 existing tumor fraction remained at a low level during immunotherapy treatment, while *de novo*
759 tumor fraction increased. This implies a potential clonality change during treatment. In other words,
760 the responding clone might have shrunk while the other clones grew. Existing cancer monitoring
761 methods, which do not consider newly emerging mutations, could not have recognized this tumor
762 growth and would have misled further treatments.

763
764 The four ovarian cancer patients received chemotherapy (OV1, OV2, and OV3) or chemotherapy
765 and surgery (OV4) between the collection of two serum samples (Supplementary Table 3). At the
766 time of the second collection, patients OV1, OV2, and OV3 underwent surgery. Surgical and
767 pathologic findings demonstrated a moderate treatment effect from chemotherapy. We observed
768 a decrease in both tumor fractions using *cfTrack* (Figure 5b), which indicated a decline in tumor
769 burden. Patient OV4 had a recurrence after chemotherapy and surgery at the time of the second
770 serum collection. Consistently, we observed an increase in both tumor fractions (Figure 5b).
771 Therefore, our results are consistent with the clinical outcomes of these patients.


772
773 We also tracked the tumor changes in the 12 prostate cancer patients who received various
774 treatment types during the time between the two plasma collections. During treatment, 9 patients
775 (P8, P9, P10, P14, P15, P16, P18, P19, and P20) had clonal expansion and 3 patients (P6, P17,
776 and P21) had persistent clones [26]. The clonality change can be reflected by the discordance of
777 the two estimated tumor fractions. In general, we observed discordance between the two tumor
778 fractions in the majority of the patients with clonal expansion (Figure 5c). There are no or only

779 minor differences between the two tumor fractions in the patients with relatively stable clones
780 (Figure 5c). These observations are consistent with those from the NSCLC patients.

781

782 From the analysis of this heterogeneous cohort of cancer patients with different cancer types and
783 various treatments, we showed that our method can not only closely track the change in tumor
784 fraction, but also detect changes in mutation clonality. The latter is essential for the detection of
785 resistance clones in order to promptly guide subsequent treatments, but it cannot be achieved by
786 existing cancer monitoring methods.

787



788

789 **Figure 5. Longitudinal cfDNA monitoring in cancer patients who received treatments.** The lines show the tumor

790 fraction in cfDNA during treatment. **(a)** Tumor fraction in plasma samples of 8 NSCLC patients who received anti-

791 PD-1 immunotherapy. **(b)** Tumor fraction in serum samples of 4 ovarian cancer patients. **(c)** Tumor fraction in plasma

792 samples of 12 prostate cancer patients.

793

794

795 **Discussion**

796 Cancer monitoring is essential to assess the effectiveness of treatment and improve the life quality
797 of cancer patients. Unlike traditional tumor biopsies, cfDNA can provide noninvasive and
798 continuous monitoring of cancer patients, but the very low tumor content of cfDNA remains a
799 major challenge. Most current cfDNA-based methods rely on deeply sequencing a small gene
800 panel to detect the weak tumor signal, but this approach cannot comprehensively cover the
801 patient population or detect evolving tumors. Therefore, we have developed a new cfDNA-based
802 cancer monitoring method that can effectively and sensitively track changes in tumors, detect
803 cancer MRD/recurrence, and identify the presence of a second primary cancer. We present a
804 new computation method for cancer monitoring using cfDNA WES data to overcome the
805 limitations of previous methods. Taking advantage of the wide genome coverage of WES data,
806 *cfTrack* (1) enhances the tumor signal by integrating a large number of clonal tumor mutations
807 identified in pre-treatment samples; (2) suppresses sequencing errors at the read level with an
808 accurate random forest model; (3) builds sample-specific background noise distributions to predict
809 MRD/recurrence, avoiding biases due to inter-individual and inter-experimental variations; and (4)
810 detects tumor evolution and second primary cancers by *de novo* identifying emerging tumor
811 mutations.

812
813 Combining these techniques, *cfTrack* achieves sensitive and specific detection of recurrence,
814 MRD and second primary cancers. In detecting recurrence in samples with a 0.05% tumor fraction,
815 *cfTrack* achieved an AUC of 99% (100% sensitivity and 96% specificity) on the validation dataset
816 and an AUC of 100% (89% sensitivity and 100% specificity) on the independent dataset. In
817 detecting second primary cancers in samples with a 0.2% tumor fraction, *cfTrack* yielded an AUC
818 of 88% (76% sensitivity and 93% specificity). Since the performance of the method increases with
819 the sequencing depth, these results can be further improved in practice. As an application, we
820 show that *cfTrack* achieved accurate and comprehensive monitoring of the changes in tumors for

821 patients with different cancer types and undergoing various treatments, which cannot be
822 accomplished by methods focusing only on a small panel of mutations from pre-treatment tumor
823 samples.

824
825 This study has its limitations. Firstly, *cfTrack* has only been validated and evaluated using *in silico*
826 spike-in simulation data and on a limited number of cancer patients. To address this limitation, we
827 generated simulation data that mimic real scenarios, including tumor evolution during treatment.
828 For example, simulated plasma samples with tumor content are generated by subsampling the
829 original plasma sample from the second time point, which already contains a different tumor
830 profile compared to the sample at baseline. Nevertheless, we acknowledge that real cases of
831 MRD, recurrence and second primary cancers could be more complicated. Applying *cfTrack* to
832 larger datasets would enable a more comprehensive evaluation and possible optimization of
833 parameters. Secondly, tumor fraction is calculated as an average across all reads for a predefined
834 list of tumor markers. Tumor evolution and tumor heterogeneity could bias the selection of
835 markers, resulting in the absence of important variant supporting reads in the post-treatment
836 cfDNA samples and causing the model to infer a lower tumor fraction. Thirdly, given the medium
837 depth of WES data and the low tumor fraction in the cfDNA samples, *cfTrack* focuses on tracking
838 the overall tumor changes rather than specific clones/subclones. For the same reason, *cfTrack*
839 can detect *de novo* mutations to monitor newly emerging tumors, but it doesn't guarantee the
840 detection of specific variants directly related to treatment targets.

841
842 In this study, for some patients, we use plasma samples to detect the pre-existing tumor mutations,
843 with no need for solid tumor biopsy samples. This is possible as long as the tumor content in
844 plasma samples is sufficient for mutation detection. For patients who receive surgical tumor
845 removal or for patients whose tumor biopsy samples are available, our method can also use a

846 solid tumor sample to identify the pre-existing tumor mutations. However, it is worth noting that a
847 plasma sample may still offer a more comprehensive mutation profile than a biopsy sample [29].

848
849 Currently, *cfTrack* utilizes tumor somatic mutations to detect cancer. In a future version, more
850 cancer-specific features in cfDNA can be incorporated. Recent studies have discovered that copy
851 number variations, fragment length, and jagged ends of cfDNA are all associated with tumor-
852 derived cfDNA. In our random forest model, we incorporated the fragment length of the DNA
853 fragments to discriminate true variants from sequencing errors. By integrating other features, we
854 may further empower cancer monitoring to provide actionable information and treatment guidance
855 for patients.

856

857

858

859 **Declaration**

860

861 **Availability of data and materials.** *cfTrack* is implemented in Python and is freely available for
862 academic and research usage through our lab website. The sequence data of the eight NSCLC
863 patients and the four ovarian cancer patients are deposited at the European Genome-phenome
864 Archive (EGA) before publication.

865

866

867

868

869

870

871 **References**

- 872 [1] Mahvi, David A., et al. "Local cancer recurrence: the realities, challenges, and opportunities for new
873 therapies." *CA: a cancer journal for clinicians* 68.6 (2018): 488-505.
- 874 [2] Chaudhuri, Aadel A., et al. "Early detection of molecular residual disease in localized lung cancer by
875 circulating tumor DNA profiling." *Cancer discovery* 7.12 (2017): 1394-1403.
- 876 [3] Kumar, Shaji K., and S. Vincent Rajkumar. "The current status of minimal residual disease
877 assessment in myeloma." *Leukemia* 28.2 (2014): 239-240.
- 878 [4] Murtaza, Muhammed, et al. "Multifocal clonal evolution characterized using circulating tumour DNA in
879 a case of metastatic breast cancer." *Nature communications* 6.1 (2015): 1-6.
- 880 [5] Abbosh, Christopher, et al. "Phylogenetic ctDNA analysis depicts early-stage lung cancer
881 evolution." *Nature* 545.7655 (2017): 446-451.
- 882 [6] Garcia-Murillas, Isaac, et al. "Mutation tracking in circulating tumor DNA predicts relapse in early
883 breast cancer." *Science translational medicine* 7.302 (2015): 302ra133-302ra133.
- 884 [7] Tie, Jeanne, et al. "Circulating tumor DNA analysis detects minimal residual disease and predicts
885 recurrence in patients with stage II colon cancer." *Science translational medicine* 8.346 (2016):
886 346ra92-346ra92.
- 887 [8] McDonald, Bradon R., et al. "Personalized circulating tumor DNA analysis to detect residual disease
888 after neoadjuvant therapy in breast cancer." *Science translational medicine* 11.504 (2019): eaax7392.
- 889 [9] Abbosh, Chris, et al. "Abstract CT023: Phylogenetic tracking and minimal residual disease detection
890 using ctDNA in early-stage NSCLC: A lung TRACERx study." (2020): CT023-CT023.
- 891 [10] Wan, Jonathan CM, et al. "ctDNA monitoring using patient-specific sequencing and integration of
892 variant reads." *Science translational medicine* 12.548 (2020).
- 893 [11] Zviran, Asaf, et al. "Genome-wide cell-free DNA mutational integration enables ultra-sensitive cancer
894 monitoring." *Nature Medicine* (2020): 1-11.
- 895 [12] Li, Shuo, et al. "Sensitive detection of tumor mutations from blood and its application to
896 immunotherapy prognosis." *Nature communications* 12.1 (2021): 1-14.
- 897 [13] Kothen-Hill, Steven T., et al. "Deep learning mutation prediction enables early stage lung cancer
898 detection in liquid biopsy." (2018).

- 899 [14] Jiang, Peiyong, et al. "Lengthening and shortening of plasma DNA in hepatocellular carcinoma
900 patients." *Proceedings of the National Academy of Sciences* 112.11 (2015): E1317-E1325.
- 901 [15] Mouliere, Florent, and Nitzan Rosenfeld. "Circulating tumor-derived DNA is shorter than somatic DNA
902 in plasma." *Proceedings of the National Academy of Sciences* 112.11 (2015): 3178-3179.
- 903 [16] Ma, Xiaotu, et al. "Analysis of error profiles in deep next-generation sequencing data." *Genome
904 biology* 20.1 (2019): 1-15.
- 905 [17] Adalsteinsson, Viktor A., et al. "Scalable whole-exome sequencing of cell-free DNA reveals high
906 concordance with metastatic tumors." *Nature communications* 8.1 (2017): 1-13.
- 907 [18] Eisenhauer, E. A. "Real-world evidence in the treatment of ovarian cancer." *Annals of Oncology* 28
908 (2017): viii61-viii65.
- 909 [19] Nevedomskaya, Ekaterina, Simon J. Baumgart, and Bernard Haendler. "Recent advances in prostate
910 cancer treatment and drug discovery." *International journal of molecular sciences* 19.5 (2018): 1359.
- 911 [20] Howlader, Nadia, et al. "The effect of advances in lung-cancer treatment on population
912 mortality." *New England Journal of Medicine* 383.7 (2020): 640-649.
- 913 [21] Rizvi, Naiyer A., et al. "Mutational landscape determines sensitivity to PD-1 blockade in non-small
914 cell lung cancer." *Science* 348.6230 (2015): 124-128.
- 915 [22] Horvath, Lena, et al. "Overcoming immunotherapy resistance in non-small cell lung cancer (NSCLC)-
916 novel approaches and future outlook." *Molecular Cancer* 19.1 (2020): 1-15.
- 917 [23] Ellis, Lee M., and Daniel J. Hicklin. "Resistance to targeted therapies: refining anticancer therapy in
918 the era of molecular oncology." *Clinical Cancer Research* 15.24 (2009): 7471-7478.
- 919 [24] Raguz, S., and E. Yagüe. "Resistance to chemotherapy: new treatments and novel insights into an
920 old problem." *British journal of cancer* 99.3 (2008): 387-391.
- 921 [25] Sharma, Padmanee, et al. "Primary, adaptive, and acquired resistance to cancer
922 immunotherapy." *Cell* 168.4 (2017): 707-723.
- 923 [26] Ramesh, Naveen, et al. "Decoding the evolutionary response to prostate cancer therapy by plasma
924 genome sequencing." *Genome biology* 21.1 (2020): 1-22.
- 925 [27] Tsui, Dana WY, et al. "Tumor fraction-guided cell-free DNA profiling in metastatic solid tumor
926 patients." *Genome medicine* 13.1 (2021): 1-15.

- 927 [28] Bettegowda, Chetan, et al. "Detection of circulating tumor DNA in early- and late-stage human
928 malignancies." *Science translational medicine* 6.224 (2014): 224ra24-224ra24.
- 929 [29] Bronkhorst, Abel Jacobus, Vida Ungerer, and Stefan Holdenrieder. "The emerging role of cell-free
930 DNA as a molecular marker for cancer management." *Biomolecular detection and quantification* 17
931 (2019): 100087.
- 932 [30] Garon, Edward B., et al. "Pembrolizumab for the treatment of non-small-cell lung cancer." *New
933 England Journal of Medicine* 372.21 (2015): 2018-2028.
- 934 [31] Herbst, Roy S., et al. "Pembrolizumab versus docetaxel for previously treated, PD-L1-positive,
935 advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial." *The
936 Lancet* 387.10027 (2016): 1540-1550.
- 937 [32] Li, Heng, and Richard Durbin. "Fast and accurate short read alignment with Burrows–Wheeler
938 transform." *bioinformatics* 25.14 (2009): 1754-1760.
- 939 [33] Li, Heng, et al. "The sequence alignment/map format and SAMtools." *Bioinformatics* 25.16 (2009):
940 2078-2079.
- 941 [34] Broad Institute. "Picard tools." (2016).
- 942 [35] Poplin, Ryan, et al. "Scaling accurate genetic variant discovery to tens of thousands of
943 samples." *BioRxiv* (2017): 201178.
- 944 [36] Van der Auwera, Geraldine A., et al. "From FastQ data to high-confidence variant calls: the genome
945 analysis toolkit best practices pipeline." *Current protocols in bioinformatics* 43.1 (2013): 11-10.
- 946 [37] Saunders, Christopher T., et al. "Strelka: accurate somatic small-variant calling from sequenced
947 tumor–normal sample pairs." *Bioinformatics* 28.14 (2012): 1811-1817.
- 948 [38] Cibulskis, Kristian, et al. "Sensitive detection of somatic point mutations in impure and heterogeneous
949 cancer samples." *Nature biotechnology* 31.3 (2013): 213-219.
- 950 [39] Strickler, John H., et al. "Genomic landscape of cell-free DNA in patients with colorectal
951 cancer." *Cancer discovery* 8.2 (2018): 164-173.
- 952
- 953
- 954